Stomach cancer is one of the most commonly missed cancers in India because its early symptoms are identical to ordinary indigestion. Persistent upper abdominal discomfort, early satiety, mild nausea and unexplained weight loss are the four signs patients most frequently attribute to acidity, stress or dietary habits for months before seeking investigation. By the time the diagnosis is confirmed, most cases in India are at Stage 3 or Stage 4. The signs listed below are individually non-specific but in combination, especially in patients over 45 with a family history or H. pylori infection, they warrant urgent endoscopic evaluation rather than empirical antacid therapy.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“The patients who reach us early are almost always those whose general physician didn’t treat persistent upper abdominal symptoms with antacids alone. They investigated first. That decision is what changes the outcome.”

The symptoms of early stomach cancer are almost never dramatic. They look exactly like common gut complaints and that is precisely why they get missed for so long.

• Persistent Indigestion: Indigestion or heartburn that doesn’t improve with antacids after two to three weeks or returns consistently after stopping medication is one of the most overlooked early indicators and stomach and esophageal cancer assessment at KIMS Hospital, Bangalore begins with urgent endoscopy for anyone over 45 presenting with new-onset persistent dyspepsia.
• Early Satiety: Feeling full after eating only a small amount is a symptom patients consistently normalise as poor appetite or stress, but early satiety that appears without a dietary change and persists for more than two to three weeks is a red flag for gastric tumour causing reduced stomach capacity.
• Unexplained Weight Loss: Losing weight without intentional dietary change or increased activity is a systemic cancer symptom that applies across multiple cancer types and unexplained weight loss of more than 5 percent of body weight over six months warrants investigation regardless of how benign the patient’s other symptoms appear.
• Upper Abdominal Discomfort: A vague ache or pressure in the upper abdomen that is not clearly related to meals, doesn’t respond to antacids and persists across several weeks is consistently described by patients with early gastric cancer as something they dismissed for months before it worsened.

These four symptoms together in a patient over 45 with H. pylori history, a family history of stomach cancer or a diet high in smoked and salted foods constitute a clinical indication for immediate endoscopy.

Several additional signs appear slightly later in the early disease process and are still actionable if investigated promptly.

• Nausea Without Cause: Persistent low-grade nausea without a clear dietary or medication trigger, particularly when it appears alongside early satiety or upper abdominal discomfort, is a combination that warrants endoscopic investigation rather than empirical antiemetic treatment.
• Blood in Stool or Vomit: Vomiting blood or passing dark tarry stools indicates bleeding from the upper gastrointestinal tract and robotic cancer surgery or conventional gastric resection for surgically identified stomach cancer produces significantly better outcomes when the disease is caught before this symptom appears.
• Difficulty Swallowing: Dysphagia involving solid foods progressing to softer foods is a specific symptom of tumours at the gastro-oesophageal junction, the area where the stomach meets the oesophagus, and this symptom should never be attributed to acid reflux without endoscopic confirmation.
• Anaemia Without Explanation: Iron deficiency anaemia without a clear source of blood loss in a patient over 45 requires upper and lower gastrointestinal investigation because chronic slow bleeding from an early gastric tumour is a common presentation that gets managed as dietary anaemia for months before the correct diagnosis is made.

Early stomach cancer is treatable and surgically curable. The problem is never the surgery. It is how long the diagnosis takes and for more on how early cancer signs are investigated, our blog on early signs of cancer covers the investigation approach in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to stomach cancer surgery including laparoscopic and robotic-assisted gastrectomy at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with persistent upper GI symptoms or a confirmed stomach cancer diagnosis are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Stomach Cancer Symptoms and Diagnosis
2. World Health Organization — Gastric Cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Lumpectomy in Bangalore costs INR 75,000 to 2,00,000 at private specialist centres. Mastectomy runs INR 1,00,000 to 3,50,000 with modified radical mastectomy at the higher end. These figures cover surgery, anaesthesia, theatre and a two to four day hospital stay. Lumpectomy is the smaller operation but it always requires radiation afterward, which adds INR 90,000 to 3,50,000 to the total. Mastectomy costs more upfront but avoids mandatory radiation in many cases. The right choice between the two is never purely financial. It’s driven by tumour size, margin achievability and what the tumour board recommends for that specific case.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Lumpectomy and mastectomy produce equivalent survival in appropriately selected patients. The cost difference between them is real but it should never be the deciding factor. The oncological decision comes first.”

Lumpectomy is the less expensive operative procedure but the full treatment cost including mandatory radiation is higher than the surgical fee alone.

• Operative Cost: Lumpectomy at private specialist centres in Bangalore costs INR 75,000 to 2,00,000 covering the operation, anaesthesia, theatre charges and a two day hospital stay and breast cancer treatment at high-volume oncology centres like KIMS sits toward the upper end of that range.
• Radiation Is Mandatory: Every lumpectomy requires radiation to the remaining breast tissue and a complete course in Bangalore costs INR 90,000 to 3,50,000, making the total lumpectomy plus radiation cost INR 1,65,000 to 5,50,000 at private specialist centres.
• Sentinel Node Biopsy Added: Axillary staging through sentinel node biopsy runs in the same session at an additional INR 40,000 to 80,000 and the result directly determines whether adjuvant chemotherapy is added to the treatment plan after surgery.
• Oncoplastic Lumpectomy Premium: Oncoplastic techniques that reshape the breast at the time of tumour removal add a surgical premium of INR 30,000 to 80,000 over standard lumpectomy at centres with dedicated oncoplastic breast surgery capability in Bangalore.

Lumpectomy’s lower operative cost is partially offset by the mandatory radiation course that follows every breast-conserving procedure regardless of tumour biology or stage.

• Mastectomy Without Reconstruction: Simple or modified radical mastectomy at private specialist centres in Bangalore costs INR 1,00,000 to 3,50,000 covering surgery, anaesthesia, theatre and a three to five day hospital stay and robotic cancer surgery or conventional mastectomy packages at KIMS Hospital are quoted as all-inclusive figures before any procedure is booked.
• Reconstruction Adds Significantly: Immediate implant-based reconstruction adds INR 1,00,000 to 2,50,000 while flap reconstruction adds INR 2,00,000 to 5,00,000 on top of the mastectomy fee, making total mastectomy plus reconstruction cost INR 2 to 8.5 lakhs depending on technique.
• Post-Mastectomy Radiation at Stage 3: Mastectomy avoids radiation in most Stage 1 and 2 cases but Stage 3 disease requires post-mastectomy chest wall radiation regardless, adding the same INR 90,000 to 3,50,000 radiation cost to both procedures at locally advanced stages.
• Long-Term Cost Is Similar: When radiation after lumpectomy and reconstruction after mastectomy are both factored in, the total treatment cost difference between the two procedures at private specialist centres in Bangalore is smaller than the operative fee gap suggests.

The right operation is determined by oncological criteria not cost and for more on what qualifies a patient for breast conservation, our blog on breast conserving surgery covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to lumpectomy, mastectomy and oncoplastic breast surgery at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT and over 25 published clinical studies. Patients wanting a transparent cost breakdown alongside a clear surgical recommendation are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Cancer Surgery Options
2. Medijourney — Breast Cancer Treatment Cost Bangalore

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Pancreatic cancer is one of the hardest cancers to detect early because the pancreas sits deep in the abdomen and produces no reliable symptoms until the tumour is large or has spread. Most cases are diagnosed at Stage 3 or Stage 4. Early diagnosis happens in two specific situations: incidental detection on imaging ordered for another reason or systematic surveillance in patients with confirmed high-risk factors including hereditary pancreatitis, BRCA2 mutation, familial pancreatic cancer syndrome or longstanding Type 2 diabetes with unexplained weight loss.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Pancreatic cancer found early is surgically curable. The problem is the biology of the disease, not the surgery. Most patients don’t have symptoms until the window for curative resection has already closed.”

Early diagnosis relies on imaging, tumour markers and biopsy in combination rather than any single test used alone.

• CT Pancreas Protocol: A dedicated pancreatic phase CT scan is the primary imaging tool for identifying pancreatic tumours, assessing vascular involvement and staging resectability and pancreatic and bile duct cancer assessment at KIMS Hospital, Bangalore uses this as the first-line investigation for any suspected pancreatic lesion.
• Endoscopic Ultrasound: EUS provides higher resolution imaging of the pancreatic head, body and tail than CT alone and allows fine needle aspiration biopsy of lesions too small to sample by percutaneous route, making it essential for diagnosing small tumours and cystic lesions.
• CA 19-9 Tumour Marker: CA 19-9 is elevated in most pancreatic cancers but is not specific enough to use as a standalone screening test because it is also elevated in bile duct obstruction, pancreatitis and other benign conditions, making it most useful alongside imaging rather than alone.
• MRCP and PET Scan: MRCP defines ductal anatomy and identifies strictures or cystic lesions that may indicate early malignant change while PET-CT identifies metabolically active disease and confirms or excludes distant spread before any surgical decision is made.

A confirmed early-stage pancreatic tumour on imaging requires biopsy for histological diagnosis before any treatment plan is confirmed.

Systematic surveillance in high-risk individuals is currently the most clinically reliable pathway to early pancreatic cancer diagnosis.

• Hereditary Pancreatitis: Patients with confirmed hereditary pancreatitis have a 40 to 75 times higher lifetime risk of pancreatic cancer and annual EUS or MRI surveillance from age 40 is the clinical standard for this group, not a precautionary option.
• BRCA2 and PALB2 Mutations: Confirmed BRCA2 or PALB2 mutation carriers with a first-degree relative with pancreatic cancer are recommended annual EUS and MRI surveillance from age 50 or ten years before the youngest affected relative’s diagnosis age and robotic cancer surgery for resectable pancreatic lesions identified through surveillance produces significantly better outcomes than surgery for symptomatic disease.
• New Onset Diabetes Over 50: New-onset Type 2 diabetes in someone over 50 with unexplained weight loss and no family history of diabetes carries a clinically meaningful association with pancreatic cancer and warrants a dedicated pancreatic CT before attributing it to metabolic disease alone.
• Intraductal Papillary Mucinous Neoplasms: IPMNs detected incidentally on abdominal imaging are premalignant lesions that require structured surveillance with EUS or MRI every six to twelve months depending on size and morphology to detect malignant transformation before it becomes invasive.

Active surveillance in high-risk groups is where early pancreatic cancer diagnosis is actually achieved and for more on how cancer biopsy confirms diagnosis, our blog on cancer diagnosis covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to pancreatic cancer surgery including Whipple procedure, distal pancreatectomy and robotic-assisted resection at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with pancreatic lesions, incidental findings or high-risk surveillance needs are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Pancreatic Cancer Screening
2. World Health Organization — Cancer Early Detection

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Advanced breast cancer surgery in India costs INR 6 to 14 lakhs for Stage 3 disease covering surgery, chemotherapy, radiation and targeted therapy at private specialist centres. The same treatment in the USA starts at USD 40,000 and can exceed USD 1,25,000 for multimodal advanced cases. That is a cost difference of 60 to 80 percent for equivalent surgical technique, the same da Vinci robotic platform and comparable specialist training. The difference is structural, not clinical.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“The cost gap between India and the West is real and significant. What isn’t real is the assumption that lower cost means lower quality at specialist oncology centres. The comparison that matters is specialist centre to specialist centre, not country to country.”

Advanced breast cancer at Stage 3 requires a multimodal treatment plan and the cost reflects surgery plus the systemic treatment that surrounds it.

• Surgery Cost: Mastectomy with full axillary dissection at private specialist centres in Bangalore costs INR 1,50,000 to 3,50,000 and breast cancer treatment packages at KIMS Hospital covering surgery, anaesthesia, theatre and post-operative ward stay are quoted as all-inclusive figures before any procedure is booked.
• Neoadjuvant Chemotherapy: Most Stage 3 patients receive four to six cycles of chemotherapy before surgery at INR 20,000 to 1,00,000 per cycle depending on the regimen used, adding INR 1,20,000 to 6,00,000 to the total treatment cost before the operation even begins.
• Radiation After Mastectomy: Post-mastectomy chest wall radiation is standard for Stage 3 disease and a complete course costs INR 90,000 to 3,50,000 depending on the technique used with IMRT sitting at the upper end of that range.
• Targeted Therapy Cost: HER2 positive advanced breast cancer patients on trastuzumab face monthly drug costs of INR 50,000 to 1,00,000 for the full adjuvant course, making targeted therapy the largest single cost component for this subtype.

Total advanced breast cancer treatment in India runs INR 6 to 15 lakhs at private specialist centres compared to USD 40,000 to 1,25,000 for equivalent treatment in the USA.

• Same Platform, Lower Price: India’s top oncology centres use the same da Vinci robotic platform, the same FDA-approved implants and the same chemotherapy protocols as leading centres in the USA and UK and robotic cancer surgery for breast cancer at KIMS Hospital, Bangalore is performed on the same technology base as equivalent Western institutions.
• Waiting Time Advantage: NHS waiting times in the UK for breast cancer surgery can run six to twelve weeks from diagnosis. Indian specialist centres typically operate within one to three weeks of the surgical consultation, which matters clinically in aggressive subtypes where treatment delay affects outcomes.
• Follow-Up Is the Real Consideration: Patients who return home after treatment abroad need a structured handover plan to their local oncology team for the five to ten years of adjuvant hormone therapy and surveillance that follows advanced breast cancer surgery.
• Insurance Applies in Both Settings: Most Indian comprehensive health policies and international travel health plans cover cancer surgery at accredited Indian hospitals and patients should confirm cashless facility availability at the treating hospital before admission rather than relying on reimbursement.

The cost advantage of treatment in India over the USA and UK is real and consistent and for more on what to expect from cancer surgery at a specialist centre in Bangalore, our blog on cancer surgery in Bangalore covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to advanced breast cancer surgery including Stage 3 cases requiring neoadjuvant coordination, mastectomy with reconstruction and post-mastectomy radiation planning at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT and over 25 published clinical studies. International and out-of-state patients are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Cancer Treatment by Stage
2. CarePal Secure — Breast Cancer Treatment Cost India 2025

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Breast cancer surgery in South India is best handled by a surgical oncologist with specialist oncology training, high operative volume, a full range of breast surgical techniques and a structured multidisciplinary tumour board review process for every case. At MACS Clinic in Jayanagar Bangalore, Prof. Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery, a fellowship in Laparoscopic and Robotic Onco-Surgery and originator credits for RABIT, MIND and RIA-MIND to breast cancer surgery across all stages and presentations.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“The best breast cancer surgeon for any patient is the one who offers the full range of surgical options, takes every case to tumour board and never plans an operation in isolation from the systemic treatment team.”

These are the things that set Dr. Nayak’s breast cancer surgical practice apart from most alternatives in South India:

• Specialist credentials: DNB in Surgical Oncology and General Surgery combined with a fellowship in Laparoscopic and Robotic Onco-Surgery completes the specialist training pathway that separates a dedicated surgical oncologist from a general surgeon performing breast operations, and that difference directly affects margin clearance rates, axillary staging accuracy and long term outcomes.
• Technique innovation: Originator of RABIT, MIND and RIA-MIND operative techniques refined through over 25 peer-reviewed clinical studies, representing a depth of clinical contribution to surgical oncology that most breast cancer surgeons operating in South India do not carry.
• High-volume tumour board: Every patient seen by Dr. Nayak goes through full multidisciplinary tumour board review with surgical oncology, medical oncology, radiation oncology and pathology all contributing before any operation is confirmed, ensuring no surgical decision is made without collective specialist input.
• Karnataka oncology leadership: Chairman of Oncology Services across Karnataka and Executive Director of Surgical Oncology at KIMS Hospital Bangalore, a leadership position that reflects clinical standing and the trust placed in his judgement across the most complex oncology cases in the state.

Patients from Chennai, Hyderabad, Kochi and Coimbatore seek consultation at MACS Clinic because the combination of specialist training, operative volume and full tumour board review is not consistently available at the same standard elsewhere in South India. Breast cancer treatment at MACS Clinic covers the full spectrum of breast cancer surgical options where every decision starts from what your specific case actually needs.

These are the breast cancer surgical approaches available at MACS Clinic under Dr. Nayak’s care:

• Lumpectomy: Breast conserving surgery that removes the tumour and a margin of surrounding tissue while preserving the rest of the breast, appropriate for early stage cancers where tumour size and location allow adequate margin clearance without full mastectomy.
• Mastectomy: Total removal of the breast for cases where tumour extent, multifocality or genetic risk makes breast conservation clinically inappropriate, performed with immediate or delayed reconstruction planning discussed before surgery rather than after.
• Oncoplastic surgery: Combines cancer removal with immediate breast reshaping in a single procedure, preserving cosmetic outcome without compromising oncological margins, appropriate for patients where standard lumpectomy alone would result in significant volume loss or deformity.
• Sentinel node biopsy and axillary dissection: Accurate axillary staging through sentinel node biopsy for clinically node-negative disease and full axillary dissection where nodal involvement is confirmed, both performed as part of the standard breast cancer surgical pathway at MACS Clinic.

Whether your specific breast cancer case requires conservative surgery, mastectomy, reconstruction or a combination depends on your tumour biology, staging and anatomy and that decision is made through tumour board review before surgery rather than at the time of the operation. Robotic cancer surgery at MACS Clinic covers the full minimally invasive spectrum where robotic-assisted approaches are offered for appropriate breast cancer cases.

Prof. Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery, a fellowship in Laparoscopic and Robotic Onco-Surgery and originator credits for RABIT, MIND and RIA-MIND to breast cancer surgery across all stages at MACS Clinic. He chairs Oncology Services across Karnataka and serves as Executive Director of Surgical Oncology at KIMS Hospital Bangalore with over 25 published clinical studies. Every breast cancer case goes through full multidisciplinary tumour board review before any surgical plan is confirmed. Call plus 91 9482202240 to book your consultation at MACS Clinic.

Reference Links-

1. National Cancer Institute. Choosing a Cancer Doctor. https://www.cancer.gov/about-cancer/managing-care/services
2. World Health Organisation. Breast Cancer Treatment. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.